First time in 10 years: Eli Lilly’s GIP/GLP-1 dual-target agonist receives FDA approval
- FDA: Investigation into Multistate Salmonella Outbreak Linked to Jif Peanut Butter
- ABBV-951: AbbVie submits new drug application for Parkinson’s disease
- Alert: Monkeypox belongs to the same genus of Orthopoxvirus as smallpox
- New study finds new coronavirus long-term hiding in intestine and feces
- New breakthrough: This collagen can make tumor cells go dormant!
- Lilly’s blockbuster new hair loss drug is expected to be launched this year
First time in 10 years: Eli Lilly’s GIP/GLP-1 dual-target agonist receives FDA approval
- Unexplained acute hepatitis in children may be related to COVID superantigens
- How long can the patient live after heart stent surgery?
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
First time in 10 years: Eli Lilly’s GIP/GLP-1 dual-target agonist receives FDA approval.
On May 13, Eli Lilly announced that the US FDA approved the company’s glucose-dependent insulin-stimulating polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist Mounjaro (tirzepatide) listing, weekly A single injection to supplement diet and exercise to improve glycemic control in adults with type 2 diabetes.
Lilly said Mounjaro represents the first new type of diabetes drug in nearly a decade.
Mounjaro will be available in 6 doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) and will be available in Lilly’s well-established auto-injector pen with a pre-attached hidden needle that the patient cannot touch or see not.
Tirzepatide is a weekly injectable GIP and GLP-1 receptor agonist that combines the actions of two incretins into one new molecule. GIP is a hormone that complements the action of GLP-1 receptor agonists.
Preclinical models have demonstrated that GIP reduces food intake and increases energy expenditure, resulting in weight loss. And when GIP is used in combination with a GLP-1 receptor agonist, it may have a greater effect on patient blood sugar and body weight.
The approval is based on positive results from the Phase III SURPASS program, a large Phase III program consisting of 10 clinical trials planned to enroll more than 13,000 patients with type 2 diabetes, five of which are global registry studies.
These include activity-controlled studies with semaglutide 1 mg, insulin glargine, and insulin degludec. These studies evaluated Mounjaro (5mg, 10mg and 15mg) alone or in combination with commonly prescribed diabetes medications including metformin, SGLT2 inhibitors, sulfonylureas and insulin glargine. In the SURPASS program, the 5mg dose of Mounjaro reduced subjects’ A1C by an average of 1.8%-2.1%, and the 10mg and 15mg doses reduced subjects’ A1C by an average of 1.7%-2.4%.
In addition, Tirzepatide has also achieved success in weight loss. Recently, in the Phase III SURMOUNT-1 trial, the weight loss effect of tirzepatide (5mg, 10mg, 15mg) treatment group was significantly better than the placebo control group at week 72 , the average weight loss reached a maximum of 22.5% (24kg), and 63% of patients in the 15mg high-dose group lost more than 20% of their weight. Lilly said it will discuss with the FDA and seek regulatory approval for this indication.
First time in 10 years: Eli Lilly’s GIP/GLP-1 dual-target agonist receives FDA approval
(source:internet, reference only)
Disclaimer of medicaltrend.org
